Abiopharma

🔍 Sullivan Christopher Ryan (Executive)

Company: Avalo Therapeutics, Inc. (AVTX)

Report Date: 2026-04-29

Detailed Transactions and Holdings:

• Sold 8,458 shares of Common Stock at $13.0925 per share (Direct)
  Date: 2026-04-29 | Code: S | equity_swap_involved: 0 | shares_owned_after: 8,880.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 8,457 shares of Common Stock at $13.2261 per share (Direct)
  Date: 2026-04-30 | Code: S | equity_swap_involved: 0 | shares_owned_after: 423.00 | transaction_form_type: 4 | Footnotes: F1, F3

Footnotes:

• F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025.
• F2: The reported securities were sold in multiple transactions at prices ranging from $12.74 to $13.50. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
• F3: The reported securities were sold in multiple transactions at prices ranging from $12.61 to $13.54. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.